Author’s response to reviews

Title: Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- A prospective interventional clinical trial

Authors:

Shafiq Ur Rehman Cheema (shafiqcheema@yahoo.com)
Muhammad Salman Rehman (dr.salmanrehman@hotmail.com)
Ghulam Hussain . (ghkhawaja2@hotmail.com)
Sidra Shafiq Cheema (sidra1@yahoo.com)
Nooman Gilani (ngilani@hotmail.com)

Version: 5 Date: 16 Nov 2019

Author’s response to reviews:

BNEP-D-19-00295R4
Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- A prospective interventional clinical trial
Shafiq Ur Rehman Cheema; Muhammad Salman Rehman; Ghulam Hussain .; Sidra Shafiq Cheema; Nooman Gilani
BMC Nephrology

Dear Prof. Dr. Cheema,

Your manuscript "Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- A prospective interventional clinical trial" (BNEP-D-19-00295R4) has been assessed by our reviewers. Based on these reports, and my own assessment as Editor, I am pleased to inform you that it is potentially acceptable for publication in BMC Nephrology, once you have carried out some essential revisions suggested by our reviewers.

Their reports, together with any other comments, are below. Please also take a moment to check our website at https://www.editorialmanager.com/bnep/ for any additional comments that were saved as attachments. Please note that as BMC Nephrology has a policy of open peer review, you will be able to see the names of the reviewers.

If you are able to fully address these points, we would encourage you to submit a revised manuscript to BMC Nephrology.
Once you have made the necessary corrections, please submit a revised manuscript online at:

https://www.editorialmanager.com/bnep/

If you have forgotten your password, please use the 'Send Login Details' link on the login page at https://www.editorialmanager.com/bnep/. For security reasons, your password will be reset.

We request that a point-by-point response letter accompanies your revised manuscript. This letter must provide a detailed response to each reviewer/editorial point raised, describing what amendments have been made to the manuscript text and where these can be found (e.g. Methods section, line 12, page 5). If you disagree with any comments raised, please provide a detailed rebuttal to help explain and justify your decision.

Please also ensure that your revised manuscript conforms to the journal style, which can be found at the Submission Guidelines on the journal homepage.

A decision will be made once we have received your revised manuscript, which we expect by 22 Nov 2019.

Please note that you will not be able to add, remove, or change the order of authors once the editor has accepted your manuscript for publication. Any proposed changes to the authorship must be requested during peer-review, and adhere to our criteria for authorship as outlined in BioMed Central's policies. To request a change in authorship, please download the 'Request for change in authorship form' which can be found here - http://www.biomedcentral.com/about/editorialpolicies#authorship. Please note that incomplete forms will be rejected. Your request will be taken into consideration by the editor, and you will be advised whether any changes will be permitted. Please be aware that we may investigate, or ask your institute to investigate, any unauthorized attempts to change authorship or discrepancies in authorship between the submitted and revised versions of your manuscript.

We look forward to receiving your revised manuscript and please do not hesitate to contact us if you have any questions.

Best wishes,

Jing Zhang
BMC Nephrology
https://bmcnephrol.biomedcentral.com/

Editor Comments:

1. Reviewer comments

   -- Please address the remaining comments from reviewer 1, seen below.

   Response: Comment from reviewer 1 is addressed.

2. Overlap
We note that the current submission contains some textual overlap with other previously published works, in particular:

(1) Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection
http://dx.doi.org/10.3748/wjg.v23.i32.5969

(2) Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen
https://doi.org/10.1016/j.ekir.2017.04.003

This overlap mainly exists in the Background (1) and Discussion (2) sections.

While we understand that you may wish to express some of the same ideas contained in these publications, please be aware that we cannot condone the use of text from previously published work.

Please be informed that we cannot proceed with handling your manuscript before this issue is resolved, and the sections of text in question have been reformulated.

Response: Text is now edited to avoid any overlap in both Background (Page 4, line 84-86 & 92-93) and Discussion section (Page 13, line 258-262)

3. Authors' contributions

-- Please reformat this section as a paragraph.

Response: Section is reformatted as paragraph (Page 16, Line 324).

4. CONSORT

-- Please remove the CONSORT checklist file from the file inventory as it is no longer needed at this stage of the editorial process.

Response: Removed from the inventory.

5. Clean copy

-- At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files. Please ensure that all figures, tables and additional/supplementary files are cited within the text.

BMC Nephrology operates a policy of open peer review, which means that you will be able to see the names of the reviewers who provided the reports via the online peer review system. We encourage you to also view the reports there, via the action links on the left-hand side of the page, to see the names of the reviewers.
Reviewer reports:
Masanori Atsukawa (Reviewer 1): This article by Shafig Ur Rehman Cheema et al, assessed that the efficacy and safety of SOF/DCV regimen in patients on hemodialysis and they recommended full dose of SOF for patients regardless of ESRD state.

Minor point
Authors should cite the bellow articles and describe the priority of SOF based regimen compared to other regimen described in Discussion section.


Although efficacy of ombitasvir/paritaprevir/ritonavir in dialysis patients has already reported, ritonavir has many drug-drug interactions.

Response: Article cited as endorsed (Page 12, line 240).

Meghan E. Sise (Reviewer 2): Authors responses address prior concerns.

-------------------
Editorial Policies
-------------------
Please read the following information and revise your manuscript as necessary. If your manuscript does not adhere to our editorial requirements, this may cause a delay while this is addressed. Failure to adhere to our policies may result in rejection of your manuscript.

In accordance with BioMed Central editorial policies and formatting guidelines, all manuscript submissions to BMC Nephrology must contain a Declarations section which includes the mandatory sub-sections listed below. Please refer to the journal's Submission Guidelines web page for information regarding the criteria for each sub-section (https://bmcnephrol.biomedcentral.com/).

Where a mandatory Declarations section is not relevant to your study design or article type, please write "Not applicable" in these sections.

For the 'Availability of data and materials' section, please provide information about where the data supporting your findings can be found. We encourage authors to deposit their datasets in publicly available repositories (where available and appropriate), or to be presented within the manuscript and/or additional supporting files. Please note that identifying/confidential patient data should not be shared. Authors who do not wish to share their data must confirm this under this sub-heading and also provide their reasons. For further guidance on how to format this section, please refer to BioMed Central's editorial policies page (see links below).

Declarations
- Ethics approval and consent to participate
- Consent to publish
Further information about our editorial policies can be found at the following links:
Ethical approval and consent:
http://www.biomedcentral.com/about/editoralpolicies#Ethics
Availability of data and materials section:
http://www.biomedcentral.com/submissions/editoral-policies#availability+of+data+and+materials

Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at https://www.springernature.com/production-privacy-policy. If you no longer wish to receive messages from this journal or you have questions regarding database management, please contact the Publication Office at the link below.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: https://www.editorialmanager.com/bnep/login.asp?a=r). Please contact the publication office if you have any questions.